ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01220141
Recruitment Status : Completed
First Posted : October 13, 2010
Last Update Posted : April 16, 2015
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This study is conducted in Europe and Asia. The aim of this observational study is to monitor antibody formation towards the room temperature stable formulation of NovoSeven® (activated recombinant human factor VII).

Condition or disease Intervention/treatment
Congenital Bleeding Disorder Haemophilia A Haemophilia B Drug: activated recombinant human factor VII

Study Type : Observational
Actual Enrollment : 51 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Observational Study on NovoSeven® Room Temperature Stable (VII25) in Patients With Haemophilia A or B
Study Start Date : November 2010
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemophilia
U.S. FDA Resources

Group/Cohort Intervention/treatment
A Drug: activated recombinant human factor VII
Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.



Primary Outcome Measures :
  1. Reduced therapeutic response and neutralising antibodies to activated recombinant human factor VII as confirmed by central laboratory [ Time Frame: after 25 exposure days ]

Secondary Outcome Measures :
  1. Adverse events reported as potentially related to activated recombinant human factor VII [ Time Frame: after 25 exposure days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Male patients with haemophilia A or B with inhibitors treated with room temperature stable NovoSeven® (activated recombinant human factor VII).
Criteria

Inclusion Criteria:

  • Diagnosed with congenital haemophilia A or B with inhibitors to factor VIII or factor IX
  • Treated with room temperature stable NovoSeven®

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01220141


Locations
Argentina
Prov. de Buenos Aires, Argentina, B1636DSU
Austria
Vienna, Austria, A-1010
Belgium
Brussels, Belgium, 1070
France
Paris La défense cedex, France, 92932
Germany
Mainz, Germany, 55127
Hungary
Budapest, Hungary, 1025
Iran, Islamic Republic of
Teheran, Iran, Islamic Republic of
Ireland
Dublin 2, Ireland
Italy
Rome, Italy, 00144
Poland
Warszawa, Poland, PL-02-274
Portugal
Paco de Arcos, Portugal, 2780-730
Slovakia
Bratislava, Slovakia, 811 05
Sweden
Malmö, Sweden, 202 15
United Kingdom
Crawley, United Kingdom, RH11 9RT
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01220141     History of Changes
Other Study ID Numbers: NN7025-3601
U1111-1116-2012 ( Other Identifier: WHO )
First Posted: October 13, 2010    Key Record Dates
Last Update Posted: April 16, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Hemophilia A
Hemophilia B
Blood Coagulation Disorders
Hemostatic Disorders
Blood Coagulation Disorders, Inherited
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Vascular Diseases
Cardiovascular Diseases
Factor VIII
Coagulants